Cent Eur J Public Health 2022, 30(Supplement):S05-S10 | DOI: 10.21101/cejph.a6806

Prevalence of cardiovascular risk factors in patients with psoriasis

Tomáš Kampe1, Erik Dorko2, Kvetoslava Rimárová2, Andrea Houžvičková2, Janette Baloghová1, Zuzana Baranová1, Matúš Madleňák3, Igor Rohoň3
1 Department of Dermatovenerology, Faculty of Medicine, Pavol Jozef Šafárik University and Louis Pasteur University Hospital in Košice, Košice, Slovak Republic
2 Department of Public Health and Hygiene, Faculty of Medicine, Pavol Jozef Šafárik University in Košice, Košice, Slovak Republic
3 Department of Dermatovenerology, Jessenius Faculty of Medicine, Martin, Slovak Republic

Objectives: The main goal of the study was to describe the demographic, epidemiological, clinical and laboratory characteristics of a monitored group of patients with psoriasis to assess the prevalence of cardiovascular comorbidities and to define the cardiovascular risk profile.

Methods: One hundred and ninety outpatients aged over 18 were included in the prospective observational cross-sectional study. Demographic and clinical data were obtained from patients. The severity of psoriasis was evaluated using the Psoriasis Area and Severity Index (PASI) and the Dermatology Life Quality Index (DLQI). The results of laboratory testing were identified based on patient health records.

Results: Based on an evaluation of psoriasis phenotypes, 150 patients (78.95%) suffered from plaque psoriasis, 18 (9.5%) from palmoplantar psoriasis, 11 (5.8%) from guttate psoriasis, 6 (3.2%) from generalized pustular psoriasis, and 5 (2.6%) from erythrodermic psoriasis. The personal medical history discovered the occurrence of arterial hypertension in 83 patients (43.7%), the occurrence of depression in 49 patients (25.8%), type 2 diabetes in 29 patients (15.3%), and dyslipidaemia in 48 patients (25.3%).

Conclusion: It is noteworthy that psoriasis may be demonstrated as a multi-system disease which does not only affect the skin and its adnexa. The association of psoriasis with comorbidities may significantly increase morbidity and total mortality as well as the demands for health care provision.

Keywords: psoriasis, comorbidities, arterial hypertension, depression, diabetes mellitus, metabolic syndrome

Received: February 20, 2021; Revised: November 30, 2021; Accepted: November 30, 2021; Published: June 27, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kampe T, Dorko E, Rimárová K, Houžvičková A, Baloghová J, Baranová Z, et al.. Prevalence of cardiovascular risk factors in patients with psoriasis. Cent Eur J Public Health. 2022;30(Supplement):S05-10. doi: 10.21101/cejph.a6806. PubMed PMID: 35841218.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM; Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013 Feb;133(2):377-85. Go to original source... Go to PubMed...
    2. deMasson A, Bouaziz JD, Battistella M, Bagot M, Bensussan A. Immunopathology of psoriasis: from bench to bedside. Med Sci (Paris). 2016;32(3):253-9. (In French.) Go to original source... Go to PubMed...
    3. Reich K. The concept of psoriasis as a systemic inflammation: implications for disease management. J Eur Acad Dermatol Venereol. 2012 Mar;26(Suppl 2):3-11. Go to original source... Go to PubMed...
    4. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2010 Apr;31(8):1000-6. Go to original source... Go to PubMed...
    5. Gulliver WP. Importance of screening for comorbidities in psoriasis patients. Exp Rev Dermatol. 2008;3(2):133-5. Go to original source...
    6. Gelfand JM, Troxel AB, Lewis JD, Kurd SK, Shin DB, Wang X, et al. The risk of mortality in patients with psoriasis. Arch Dermatol. 2007;143(12):1493-9. Go to original source... Go to PubMed...
    7. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome [Internet]. Brussels: IDF; 2006 [cited 2021 Nov 30]. Available from: https://www.idf.org/e-library/consensus-statements/60-idfconsensus-worldwide-definitionof-the-metabolic-syndrome.html.
    8. Sundarrajan S, Arumugam M. Comorbidities of psoriasis - exploring the links by network approach. PloS One. 2016;11(3):e0149175. doi: 10.1371/journal.pone.0149175. Go to original source... Go to PubMed...
    9. Sninčák M, Balažovjech I, Macháčová. Blood pressure in Slovakia. Prevalence of hypertension, awareness, treatment and its effectiveness in a representative stratified group. KESHSR 2004. Vnitr Lek. 2005;51(10):1184-5. (In Slovak.)
    10. Takeshita J, Wang S, Shin DB, Mehta NN, Kimmel SE, Margolis DJ, et al. Effect of psoriasis severity on hypertension control: a population-based study in the United Kingdom. JAMA Dermatol. 2015 Feb;151(2):161-9. Go to original source... Go to PubMed...
    11. Galajda P, Mokáň M, Prídavková D, Tomášková V, Šutarík L, Kručinská L, et al. Prevalence of metabolic syndrome in Slovakia. Int Med. 2007;7(6):325-31. (In Slovak).
    12. Gisondi P, Tessari A, Conti S, Piaserico S, Schianchi S, Peserico A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol. 2007;157(1):68-73. Go to original source... Go to PubMed...
    13. Langan SM, Seminara NM, Shin DB, Troxel AB, Kimmel SE, Mehta NN, et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol. 2012 Mar;132(3 Pt 1):556-62. Go to original source... Go to PubMed...
    14. Ma C, Harskamp CT, Armstrong EJ, Armstrong AW. The association between psoriasis and dyslipidaemia: a systematic review. Br J Dermatol. 2013;168(3):486-95. Go to original source... Go to PubMed...
    15. Armstrong AW, Harskamp CT, Dhillon JS, Armstrong EJ. Psoriasis and smoking: a systematic review and meta-analysis. Br J Dermatol. 2014 Feb;170(2):304-14. Go to original source... Go to PubMed...
    16. Velčická J. A look at the health status of the population of the Slovak Republic and its determinants (EHIS 2014 results). Bratislava: Statistical Office of the Slovak Republic; 2015. (In Slovak.)
    17. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006;298(7):321-8. Go to original source... Go to PubMed...
    18. Korman AM, Hill D, Alikhan A, Feldman SR. Impact and management of depression in psoriasis patients. Expert Opin Pharmacother. 2016;17(2):147-52. Go to original source... Go to PubMed...
    19. Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes. 2012 Dec 3;2(12):e54. doi: 10.1038/nutd.2012.26. Go to original source... Go to PubMed...
    20. Gisondi P, Farina S, Giordano MV, Girolomoni G. Usefulness of the Framingham risk score in patients with chronic psoriasis. Am J Cardiol. 2010;106(12):1754-7. Go to original source... Go to PubMed...
    21. Fernández-Torres R, Pita-Fernández S, Fonseca E. Psoriasis and cardiovascular risk. Assessment by different cardiovascular risk scores. J Eur Acad Dermatol Venereol. 2013 Dec;27(12):1566-70. Go to original source... Go to PubMed...

    Return to the content